Endogenous / BiologyEndogenousHuman-supportedUpdated 2026-04-24

Peptide reference file

GnRH / Gonadorelin

Trending #26 in Endogenous8.4k searches/moProven

GnRH, also called gonadorelin in drug contexts, is the endogenous releasing hormone that controls LH and FSH signaling through the pituitary.

Current readout: human-supported evidence, endogenous status, endogenous approval state, human evidence appears in the current trail, registered trials are linked, and 3 linked sources in the seed trail.

PubChem CID 638793 | 49416 PubMed results | 1127 trial records | 5 DailyMed labels | 2 Drugs@FDA applications

GnRH / Gonadorelin is mostly discussed because it is the root biology behind multiple approved GnRH agonists and antagonists.

The public claim is straightforward: It is the root biology behind multiple approved GnRH agonists and antagonists. Core endocrine peptide entry with direct clinical relevance.

In plain language, gnRH, also called gonadorelin in drug contexts, is the endogenous releasing hormone that controls LH and FSH signaling through the pituitary.

Human-supportedEndogenous
Reproductive axisPituitary signalingGonadotropin release

Aliases: Gonadorelin, GnRH

SpecimenGnRH / Gonadorelin specimen
CCCCCHHHHHHHNNO
Formula
C55H75N17O13
Mass
1182.3
Evidence
Human-supported
Elements
4

Most commonly discussed in relation to Reproductive axis, Pituitary signaling, Gonadotropin release.

What GnRH / Gonadorelin is

GnRH, also called gonadorelin in drug contexts, is the endogenous releasing hormone that controls LH and FSH signaling through the pituitary.

GnRH / Gonadorelin is grouped under Endogenous / Biology / Approved / Clinical on PeptideFactCheck because it is the root biology behind multiple approved GnRH agonists and antagonists.

The useful starting point is to separate the molecule itself from the internet story around it. It is the root biology behind multiple approved GnRH agonists and antagonists.

Why people keep looking it up

It is the root biology behind multiple approved GnRH agonists and antagonists.

GnRH, also called gonadorelin in drug contexts, is the endogenous releasing hormone that controls LH and FSH signaling through the pituitary.

GnRH / Gonadorelin tends to stay in the conversation because it touches a familiar public theme: reproductive axis, pituitary signaling, and gonadotropin release. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Core endocrine peptide entry with direct clinical relevance.

Human endocrine physiology is well established and clinically important.

Mechanistic support around reproductive-axis control is strong.

Why this page carries the current tier: Core endocrine peptide entry with direct clinical relevance.

The current seed trail for GnRH / Gonadorelin is pulling from 2 databases sources and 1 literature source.

Safety, limits, and regulatory context

The native hormone, diagnostic use, and long-acting analog drugs should be kept distinct.

GnRH is tracked here as endogenous biology rather than a single brand-level FDA-approved profile.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for GnRH / Gonadorelin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for GnRH / Gonadorelin is CID 638793. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
638793
Formula
C55H75N17O13
Molecular weight
1182.3
InChIKey
XLXSAKCOAKORKW-AQJXLSMYSA-N

Matched synonyms include GONADORELIN, Gonadorelina, GnRH-I, Gonadorelinum, 33515-09-2, Fertagyl, LH-Releasing factor, Luforan.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for GnRH / Gonadorelin returns 1127 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for GnRH / Gonadorelin returns 49416 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Label and regulatory records

For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.